Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis

Phase 3positiveXIAFLEX®Positive

AI Analysis

Summary

Keenova Therapeutics announced positive Phase 3 results for XIAFLEX (collagenase clostridium histolyticum) in treating plantar fibromatosis. The positive trial outcome supports potential regulatory advancement for this indication.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Importance:7/10

Sentiment:

0.80

Phase 3positive resultsXIAFLEXplantar fibromatosiscollagenase clostridium histolyticum

Related Companies

$MDCE

Read the original article

Published by PR Newswire Biotech on July 8, 2026 11:00 AM

Read Original